Tenon Medical Posts Record 2025 Revenue as SImmetry+ Wins FDA Clearance

Overview

• Full‑year revenue reached $3.9 million, with fourth‑quarter sales of $1.5 million rising 92% year over year on growing procedure volumes and new physician adoption.
• Fourth‑quarter gross margin improved to 69% following operational efficiencies and greater leverage of the commercial infrastructure.
• FDA 510(k) clearance for the next‑generation SImmetry+ SI‑joint fusion system enables a lateral approach that complements Catamaran, with initial clinical ‘alpha’ cases completed at Centers of Excellence.
• Tenon raised $2.85 million via an ATM PIPE and $4.3 million through a private placement of senior convertible notes to fund commercial expansion, which management says provides runway into 2026.
• Following the SiVantage transaction, the company now markets multiple spine solutions, reports 29 issued U.S. patents and 31 pending applications, and plans additional near‑term FDA submissions.